Turner joined Royalty Pharma in 2021. Previously, he was a Vice President at J.P. Morgan covering large cap biotechnology companies in equity research. He had started his tenure at J.P. Morgan covering Smid cap biotechnology. Before J.P. Morgan, Turner was an associate at Flagship Pioneering in early-stage biotech investing and company creation.
Prior to medical school, Turner worked in a hematology/oncology translational research laboratory at the Beth Israel Deaconess Medical Center in Boston developing cancer vaccines for AML and MM. Turner received his BA from Bowdoin College with Honors in biochemistry and his medical degree from Tufts University.